Guillain-Barré Syndrome is a rare neurological disorder in which the body’s immune system mistakenly attacks the peripheral nerves, leading to muscle weakness, numbness, and potentially paralysis.
Dr. Rossella Spataro performed 25 recoveriX sessions with the patients and conducted both pre-assessments and post-assessments to objectively describe improvements. The patient lost the ability to walk and move his hand within 4 months and was therefore treated by Dr. Spataro in Italy.
The Medical Research Council (MRC) Scale for Muscle Strength is a commonly used scale for assessing muscle strength, ranging from Grade 5 (normal) to Grade 0 (no visible contraction). Dr. Spataro objectively described improvements by using this scale before and after recoveriX training.
Score 5: Normal; Score 4: Movement against gravity and resistance; Score 3: Movement against gravity over (almost) the full range; Score 2: Movement of the limb but not against gravity; Score 1: Visible contraction without movement of the limb (not existent for hip flexion); Score 0: No visible contraction;
Score 0: No motion/ No reflex activity; Score 1: Partial motion/ Partial reflexivity; Score 2: Full motion/ Normal reflexes;
As shown in the MRC tables, the total score improved from 10 points before the recoveriX treatment to 40 points after the treatment. This is a significant improvement after only 18 hours of effective therapy. However, what is even more impressive is watching the videos recorded before and after the recoveriX treatment. So far, this is the only patient with Guillain-Barré Syndrome who has been treated with recoveriX.
Parkinson’s disease is a progressive neurological disorder characterized by tremors, rigidity, and bradykinesia, which gradually impair movement and coordination over time. Parkinson’s patients undergo 24 recoveriX therapy sessions, along with pre-assessments and post-assessments. The following tests are performed:
We are presenting here an example of a female patient. In the two pre-assessments, the TUG time was around 26 to 27 seconds. The patient showed a significant improvement, eventually reaching approximately 13 seconds.
The 10 MWT was around 13 seconds before recoveriX treatment, and the patient quickly improved with the recoveriX treatment. By the end, the patient needed about 7 seconds.
The BBT improved for both hands and arms.
The 9HPT improved for both hands, showing better fine motor skills.
The patient reported after the recoveriX treatment that she is able to play darts with very high precision and that she has improved in archery. Currently the clinical study is ongoing.
[1] Woytowicz, E. J., Rietschel, J. C., Goodman, R. N., Conroy, S. S., Sorkin, J. D., Whitall, J., & McCombe Waller, S. (2017). Determining levels of upper extremity movement impairment by applying a cluster analysis to the Fugl-Meyer assessment of the upper extremity in chronic stroke. Archives of Physical Medicine and Rehabilitation, 98(3), 456–462. doi:10.1016/j.apmr.2016.06.023
[2] Page, S. J., Fulk, G. D., & Boyne, P. (2012). Clinically important differences for the upper-extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. Physical Therapy, 92(6), 791–798. doi:10.2522/ptj.20110009
Long COVID refers to a range of symptoms that persist for weeks or months after the acute phase of a COVID-19 infection, including fatigue, cognitive difficulties, and respiratory problems. The results of the MS study showed that recoveriX improves fatigue in patients with Multiple Sclerosis, and therefore we invited Long COVID patients to undergo 25 treatment sessions. To objectively mark improvements, we performed the following tests:
The diagram shows the improvement in gait duration with the recoveriX treatment. We performed two pre-assessments to ensure that the patient did not have fluctuations. The patient could walk around 380 meters before recoveriX and improved to about 450 meters after the recoveriX treatment. It is also interesting how quickly the patient improved.
Fatigue was significantly reduced by the recoveriX treatment, the patient slept better, and cognitive functions improved.
The fine motoric skills of both hands improved during the recoveriX therapy.
Hand and arm functions improved because of the recoveriX therapy.
So far, we have treated 3 patients with Long COVID, and we are reporting on the first patient here. The clinical study is currently ongoing.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information